Epsilon-aminocaproic acid promotes the release of α2-antiplasmin during and after cardiopulmonary bypass

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 2, 2001, Pages 129-135

  Ray, M J ^a   Hales, M ^a   Marsh, N ^b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

2 antiplasmin; Aprotinin; Cardiopulmonary bypass; Epsilon aminocaproic acid; Fibrinolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; APROTININ; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLEEDING; BLOOD LEVEL; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MEDIATOR RELEASE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; APROTININ; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEART VALVE DISEASES; HEMOSTATICS; HUMANS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0035076665     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200103000-00007     Document Type: Article

References (36)

1. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass
2. Bleeding complications associated with cardiopulmonary bypass
3. Platelet activation and aggregation during cardiopulmonary bypass
4. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery
5. Early activation of hemostasis during cardiopulmonary bypass: Evidence for thrombin mediated hyperfibrinolysis
6. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass
7. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass
8. Aprotinin therapy in cardiac operations: A report on use in 41 cardiac centers in the United Kingdom
9. Prophylactic tranexamic acid decreases bleeding after cardiac operations
10. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial
11. Comparison of the effects of epsilon-aminocaproic acid and aprotinin on intra- and postoperative bleeding in heart surgery
12. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs
13. High-dose epsilon-aminocaproic acid versus aprotinin: Antifibrinolytic efficacy in first-time coronary operations
14. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: Aprotinin vs tranexamic acid vs epsilon aminocaproic acid
15. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: A meta-analysis
16. Clinical application of inhibitors of fibrinolysis
17. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency
18. Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders
19. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis
20. Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency
21. Clinical features and treatment of herditary and acquired plasmin inhibitor deficiency
22. Reduction in requirements for allogeneic blood products: Pharmacologic methods
23. Cardiac bypass haemostasis: Putting blood through the mill
24. Aprotinin: An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery
25. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass
26. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass
27. Coagulation on biomaterials in flowing blood: Some theoretical considerations
28. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin
29. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients
30. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits
31. Antifibrinolytic therapy
32. Aprotinin
33. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass
34. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass
35. Mechanisms of physiological fibrinolysis
36. 2 antiplasmin complexes in unstable angina